To date, five CAR T-cell therapies have been approved by the US Food and Drug Administration (FDA) (1), four of which target CD19-positive B-cell leukemia and lymphoma, and one targets B-cell maturation antigen (BCMA) expressing multiple myeloma. Here, TNFRSF17 is linked to lymphoma.